Encephalopathy News and Research RSS Feed - Encephalopathy News and Research

Extremes of stroke symptoms attract misdiagnoses

Extremes of stroke symptoms attract misdiagnoses

Patients with very mild or very severe stroke symptoms are at the greatest risk of being misdiagnosed in the emergency department, research suggests. [More]
Two UM researchers receive $500,000 to improve treatment for mild traumatic brain injury

Two UM researchers receive $500,000 to improve treatment for mild traumatic brain injury

Two University of Montana researchers were among six final winners nationally to receive $500,000 from the Head Health Challenge I, an up-to-$10 million program sponsored by General Electric Co. and the National Football League. [More]
Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. [More]
New research offers potential for early intervention to prevent neurodegenerative diseases

New research offers potential for early intervention to prevent neurodegenerative diseases

New research led by investigators at Beth Israel Deaconess Medical Center provides the first direct evidence linking traumatic brain injury to Alzheimer's disease and chronic traumatic encephalopathy (CTE) -- and offers the potential for early intervention to prevent the development of these debilitating neurodegenerative diseases. [More]
Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR. [More]
Research shows how prion-like proteins critical for maintaining long-term memories

Research shows how prion-like proteins critical for maintaining long-term memories

Research from Eric Kandel's lab at Columbia University Medical Center has uncovered further evidence of a system in the brain that persistently maintains memories for long periods of time. And paradoxically, it works in the same way as mechanisms that cause mad cow disease, kuru, and other degenerative brain diseases. [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015. [More]
Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults. [More]
New article shows link between head injuries and neurodegenerative disease in rugby union players

New article shows link between head injuries and neurodegenerative disease in rugby union players

A new article publishing online today in the Quarterly Journal of Medicine has reported the first case showing an association between exposure to head injuries in rugby union players and an increased risk in neurodegenerative disease. [More]
Available research does not support link between chronic traumatic encephalopathy and sports

Available research does not support link between chronic traumatic encephalopathy and sports

Available research does not support the contention that athletes are uniquely at risk of chronic traumatic encephalopathy (CTE) or other neurodegenerative disorders, according to a review in the June issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]
CLDF collaborates with Walgreens to offer free rapid HCV testing

CLDF collaborates with Walgreens to offer free rapid HCV testing

The Chronic Liver Disease Foundation announced today that it's collaborating with Walgreens to offer free hepatitis C (HCV) testing with the OraQuick HCV Rapid Test at more than 60 Walgreens retail pharmacies in 12 major cities throughout the country. [More]
Grass plants can bind, uptake and transport infectious prions

Grass plants can bind, uptake and transport infectious prions

Grass plants can bind, uptake and transport infectious prions, according to researchers at The University of Texas Health Science Center at Houston (UTHealth). [More]
Repetitive head injuries may accelerate aging process, increase dementia risk

Repetitive head injuries may accelerate aging process, increase dementia risk

Repetitive head injuries that occur during contact sports and military service may accelerate the aging process by increasing the build-up of beta-amyloid in the brain, leading to worse disease and an increased likelihood of developing dementia. In particular, boxers fared the worst among athletes and military veterans with a history of head injuries. [More]
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]

Individuals with mild Traumatic Brain Injury show brain abnormalities in their white matter

Individuals with mild Traumatic Brain Injury (mTBI), particularly those who have had loss of consciousness (LOC), show structural brain abnormalities in their white matter as measured by Diffusion Tensor Imaging (DTI). [More]
Spanish scientists find apatite bioceramics from shark teeth for implants

Spanish scientists find apatite bioceramics from shark teeth for implants

Researchers from the BIOCAPS Area of 'Biomaterials, tissue engineering and regenerative medicine' have managed to obtain bioceramics from shark teeth, which have already tested applications in the regeneration of bone tissue, particularly in the fields of traumatology and odontology. [More]
Lupin introduces first Brand product Zaxine in Canada

Lupin introduces first Brand product Zaxine in Canada

Pharma Major Lupin Limited announced today that its Canadian subsidiary, Lupin Pharma Canada Limited (collectively Lupin) has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc. [More]
Study reveals new target for research into liver disease

Study reveals new target for research into liver disease

In a recent study, Virginia Commonwealth University School of Medicine researchers predicted which cirrhosis patients would suffer inflammations and require hospitalization by analyzing their saliva, revealing a new target for research into a disease that accounts for more than 30,000 deaths in the United States each year. [More]
Inflammation plays causal role in neurologic changes associated with Lyme disease

Inflammation plays causal role in neurologic changes associated with Lyme disease

About 15% of patients with Lyme disease develop peripheral and central nervous system involvement, often accompanied by debilitating and painful symptoms. New research indicates that inflammation plays a causal role in the array of neurologic changes associated with Lyme disease, according to a study published in The American Journal of Pathology. [More]
Advertisement
Advertisement